WALTHAM, Mass., September 5, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) will participate in the Morgan Stanley Global Healthcare Conference on Tuesday, September 10, 2019. Bill Heiden, president and chief executive officer, and Ted Myles, chief financial officer, will participate in a fireside chat at 5:15 p.m. EDT.   A live audio webcast will be accessible… More

WALTHAM, Mass., Sept. 4, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) (“AMAG” or the “Company”) today responded to the preliminary consent solicitation filed by Caligan Partners (“Caligan”) with the following statement:   “AMAG regularly engages with shareholders on a range of topics and values their constructive input and is committed to act in the best interest… More

The First FDA-Approved As-Needed Treatment for Premenopausal Women Experiencing Low Sexual Desire and Associated Distress Now Available to Patients   WALTHAM, Mass. August 27, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that Vyleesi™ (bremelanotide injection), a melanocortin receptor agonist indicated for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women, is… More

WALTHAM, Mass., August 20, 2019 — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the Board of Directors of AMAG approved inducement awards to a new employee of (i) an option to purchase 16,700 shares of common stock and (ii) 8,500, restricted stock units. The option will have an exercise price equal to the closing price of AMAG’s… More

WALTHAM, Mass., August 13, 2019 — AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that the Board of Directors of AMAG approved inducement awards to a new employee of (i) an option to purchase 14,500 shares of common stock and (ii) 7,500 restricted stock units. The option will have an exercise price equal to the closing price of AMAG’s… More

Promoted products achieved sequential and year-over-year revenue and market share growth 2019 financial guidance lowered: exiting Makena intramuscular market and removing milestone revenue Vyleesi on-track for national launch in September Conference call scheduled for 8:00 a.m. ET today   WALTHAM, MA (August 7, 2019) AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today reported unaudited consolidated financial results for… More

WALTHAM, Mass., July 29, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its second quarter 2019 financial results will be released on Wednesday, August 7, 2019 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on… More

The First FDA-Approved As-Needed Treatment for Premenopausal Women Experiencing Distress or Interpersonal Difficulty Due to Low Sexual Desire  1 in 10 Premenopausal Women in the U.S. (Approximately 6 Million Women) Suffer From HSDD WALTHAM, Mass. June 21, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced today that the U.S. Food and Drug Administration (FDA) has approved… More

AMAG Pharmaceuticals to Present at Jefferies 2019 Global Healthcare Conference   WALTHAM, Mass., May 29, 2019 – AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) today announced that William Heiden, president and chief executive officer, will present at the Jefferies 2019 Global Healthcare Conference in New York City on Wednesday, June 5, 2019 at 3:00 p.m. EDT.   A… More

FOR IMMEDIATE RELEASE   WALTHAM, MA (May 17, 2019) – AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that it will host an Analyst Day for the investment community on Wednesday, May 22, 2019 from 8:30 a.m. to 12:00 p.m. Eastern Time. Members of AMAG’s management team and key opinion leaders will provide updates on the… More